Desoxycorticosterone Pivalate

Verify with FDA CVM →

1,745 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,745
Total Reports
129
Deaths Reported
740.0%
Death Rate

Active Ingredients

Desoxycorticosterone Pivalate

Administration Routes

SubcutaneousIntramuscularUnknownParenteralIntravenousOralOtherOphthalmicCutaneous

Species Affected

Dog 1,573
Unknown 152
Cat 10
Monkey 7
Human 2
Goat 1

Most Affected Breeds

Retriever - Labrador 204
Unknown 155
Crossbred Canine/dog 107
Dog (unknown) 79
Poodle - Standard 78
Chihuahua 51
Beagle 48
Deutsche Dogge, Great Dane 39
Retriever - Golden 39
Pointing Dog - German Short-haired 39

Most Reported Reactions

Immediate pain upon injection 247
Lethargy (see also Central nervous system depression in 'Neurological') 228
Vomiting 204
Polyuria 196
Polydipsia 192
Other abnormal test result NOS 160
High sodium-potassium ratio (Na:K ratio) 159
Diarrhoea 156
Lack of efficacy - NOS 131
Anorexia 124
Vocalisation 118
Weight gain 83

Outcome Breakdown

Recovered/Normal
584 (42.1%)
Outcome Unknown
448 (32.3%)
Ongoing
219 (15.8%)
Died
67 (4.8%)
Euthanized
62 (4.5%)
Recovered with Sequela
8 (0.6%)

Data Summary

Metric Value
Total adverse event reports 1,745
Reports involving death 129
Case-fatality rate (reported events) 740.0%
Distinct species in reports 6
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Desoxycorticosterone Pivalate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,745 adverse event reports referencing Desoxycorticosterone Pivalate, including 129 reports in which the animal died — a 740.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Desoxycorticosterone Pivalate. Reported administration routes include Subcutaneous, Intramuscular, Unknown, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Desoxycorticosterone Pivalate reports are Dog (1,573 reports), Unknown (152 reports), Cat (10 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (204), Unknown (155), Crossbred Canine/dog (107) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Desoxycorticosterone Pivalate are Immediate pain upon injection (247), Lethargy (see also Central nervous system depression in 'Neurological') (228), Vomiting (204), Polyuria (196). Of the 1,388 reports with a coded outcome, Recovered/Normal is the leading category at 42.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Desoxycorticosterone Pivalate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial